Targeting oxidative stress in disease: promise and limitations of antioxidant therapy

HJ Forman, H Zhang - Nature Reviews Drug Discovery, 2021 - nature.com
Oxidative stress is a component of many diseases, including atherosclerosis, chronic
obstructive pulmonary disease, Alzheimer disease and cancer. Although numerous small …

Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment

N Samsu - BioMed research international, 2021 - Wiley Online Library
Diabetic nephropathy (DN) is the leading cause of end‐stage renal disease worldwide.
Chronic hyperglycemia and high blood pressure are the main risk factors for the …

Diagnosis and treatment of multiple sclerosis: a review

MP McGinley, CH Goldschmidt, AD Rae-Grant - Jama, 2021 - jamanetwork.com
Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

An overview of Nrf2 signaling pathway and its role in inflammation

S Saha, B Buttari, E Panieri, E Profumo, L Saso - Molecules, 2020 - mdpi.com
Inflammation is a key driver in many pathological conditions such as allergy, cancer,
Alzheimer's disease, and many others, and the current state of available drugs prompted …

Treatment of multiple sclerosis: a review

SL Hauser, BAC Cree - The American journal of medicine, 2020 - Elsevier
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Myopia

PN Baird, SM Saw, C Lanca, JA Guggenheim… - Nature reviews Disease …, 2020 - nature.com
Myopia, also known as short-sightedness or near-sightedness, is a very common condition
that typically starts in childhood. Severe forms of myopia (pathologic myopia) are associated …

[HTML][HTML] Molecular basis of the KEAP1-NRF2 signaling pathway

T Suzuki, J Takahashi, M Yamamoto - Molecules and cells, 2023 - Elsevier
Transcription factor NRF2 (NF-E2-related factor 2) is a master regulator of cellular responses
against environmental stresses. NRF2 induces expression of detoxification and antioxidant …

Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial

L Kappos, RJ Fox, M Burcklen, MS Freedman… - JAMA …, 2021 - jamanetwork.com
Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …

Activators and inhibitors of NRF2: a review of their potential for clinical development

N Robledinos-Antón… - Oxidative medicine …, 2019 - Wiley Online Library
The transcription factor NRF2 (nuclear factor erythroid 2‐related factor 2) triggers the first
line of homeostatic responses against a plethora of environmental or endogenous …

Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies

T Spelman, M Magyari, F Piehl, A Svenningsson… - JAMA …, 2021 - jamanetwork.com
Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …